Bausch Health (BHC) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
A Special Meeting is scheduled for October 7, 2025, to ratify and approve the Shareholder Rights Plan Agreement adopted on April 14, 2025.
The meeting will be held virtually, allowing shareholders to vote and ask questions online.
The Rights Plan aims to ensure fair treatment of all shareholders in the event of unsolicited take-over bids or acquisition attempts.
The Board recommends voting in favor of the Rights Plan, which is not in response to any specific acquisition proposal.
Voting matters and shareholder proposals
Shareholders are asked to approve the ratification of the Rights Agreement as the sole proposal at the meeting.
Approval requires a simple majority of votes cast, with specific provisions for excluding certain large shareholders if applicable.
No other matters are currently anticipated for the meeting.
Board of directors and corporate governance
The Board adopted the Rights Plan in compliance with a prior Director Appointment and Nomination Agreement and best practices.
Shareholders can communicate with the Board via email, mail, or a dedicated helpline.
Latest events from Bausch Health
- 11th straight quarter of revenue and EBITDA growth, with strong segment results and lower net debt.BHC
Q4 202520 Feb 2026 - Q2 2024 revenue up 11% to $2.40B, adjusted EBITDA up 10%, and debt reduced by $360M.BHC
Q2 20242 Feb 2026 - Q3 revenue up 12%, Adjusted EBITDA up 10%, guidance raised, and all segments grew.BHC
Q3 202417 Jan 2026 - Strong 2024 results and 2025 growth outlook driven by GI, aesthetics, and neuroscience franchises.BHC
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026 - Full-year revenue and adjusted EBITDA rose 10%, with all segments contributing to growth.BHC
Q4 202429 Dec 2025 - Q1 2025 revenue up 5% to $2.26B; $7.9B refinancing extends debt maturities and boosts flexibility.BHC
Q1 202522 Dec 2025 - Growth in GI, Solta, and international markets, with XIFAXAN exclusivity and trial data as key focus.BHC
Evercore ISI 8th Annual HealthCONx Conference3 Dec 2025 - Board recommends approval of all annual meeting proposals, with strong governance and ESG focus.BHC
Proxy Filing2 Dec 2025 - Shareholders will vote to ratify a Rights Plan ensuring fair treatment in take-over bids.BHC
Proxy Filing2 Dec 2025